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Pax5hetase (FDPS) is a key enzyme in the isoprenoid pathway responsible for
cholesterol biosynthesis, post-translational protein modiﬁcations and synthesis of steroid hormones, whose
expression is regulated by phorbol esters and polyunsaturated fatty acids.
Genomic comparison of the 5′ upstream sequence of the FDPS genes identiﬁes conserved binding sites
for NF-Y, SP1, SRE3, and YY1 regulatory elements in rat, mouse, dog and chimpanzee. Two additional speciﬁc
consensus sequences, upstream of the core promoter that had not been analysed previously, are shared only
by human and chimpanzee genomes.
The work presented here aimed at characterizing these genomic sequence elements in the human FDPS
promoter region and their contribution to gene expression. We have characterized functionally the minimal
basal promoter of the human FDPS gene by means of deletion mutants and we have identiﬁed two cis-acting
elements which modulate the FDPS gene expression and are recognized by Pax5 and OCT-1 transcription
factors.
© 2008 Elsevier Inc. All rights reserved.IntroductionFarnesyl diphosphate synthetase (FDPS; EC 2.5.1.1/EC 2.5.1.10) is a
polyprenyltransferase that catalyzes the synthesis of farnesyl pyr-
ophosphate (FPP) by the sequential 1′–4 condensation of dimethilallyl
diphosphate with two molecules of isopentenyl diphosphate. [1].
FDPS is a key enzyme in isoprenoid biosynthetic pathway. The product
of its catalytic activity, FPP, is a common intermediate in the synthesis
of both sterol and non-sterol isoprenoid compounds. They are
represented by cholesterol, ubiquinone, dolichol, and metabolites
necessary for post-translational prenylation of small GTPases that are
involved in cell growth and survival, motility, cytoskeletal regulation,
intracellular transport, and secretion [2–5]. Given the essential role of
this pathway in several clinical conditions, new drugs have been
developed to inhibit the activity of the key enzymes in the isoprenoid
synthesis, such as statins which inhibit the hydroxymethylglutaryl-
CoA reductase (HMGCR) to lower cholesterol levels, or farnesyl trans-
ferase inhibitors (FTIs) for the treatment of cancer [6]. FDPS activity, in
particular, is inhibited by nitrogen-containing bisphosphonates (N-
BPs), that are used as bone antiresorptive drugs in disorders such as
osteoporosis, Paget disease, or multiple myeloma [7,8]. FDPS is most
likely the molecular target of N-BPs, synthetic analogues of inorganicantile e di Biologia-Genetica,
di Verona, Strada le Grazie, 8,
. Romanelli).
l rights reserved.pyrophosphate [9]. N-BPs are potent inhibitors of FDPS [10–14] and
prevent the synthesis of prenilated proteins involved in the regulation
of a variety of osteoclast cell processes, including cytoskeletal arrange-
ment, membrane rufﬂing, trafﬁcking of intracellular vesicles and apo-
ptosis [15–18]. Studies in Dictyostelium discoideum have demonstrated
that over-expression of FDPS leads to resistance to the growth-
inhibitory effect of N-BPs [12,19]. The expression of human and rat
FDPS gene has been demonstrated to be regulated by phorbol esters
[20]. Dietary polyunsaturated fatty acids (PUFAs) suppress transcrip-
tion of hepatic FDPS, actingon lipogenic transcriptional factor SREBP-1c
(SREBF1) and modulating NF-Y binding to regulatory elements in the
promoter region [21,22]. FDPS is an alternatively spliced gene encoding
for at least two major isoforms in eukaryotes: one is localized in
peroxisomes, despite its lack of a peroxisome targeting sequence [23]; a
second one is a mitochondrial isoform that has been detected in
humans, fruit ﬂies and plants [24,25]. FDPS genes have been recently
characterized in basidiomycetus fungus [26]. Variations in the FDPS
enzyme activity have been related to human diseases. A reduced
activity of FDPS has been demonstrated in the hepatic tissue of patients
with peroxisomal disorders such as Zellweger disease and neonatal
adrenoleukodystrophy [27]. In addition, preliminary results associate a
single nucleotide polymorphism in the FDPS gene to lower bone
mineral density in postmenopausal Caucasian women [28]. Functional
analysis of the promoter region of the gene has been performed in rat.
In this animal model, FDPS gene encodes different mRNA transcripts
that show different translational efﬁciency, tissue distribution and
transcriptional regulation. Two major representative rat FDPS mRNAs
228 M.G. Romanelli et al. / Genomics 93 (2009) 227–234differing in the length of the 5′ untranslated region, are expressedwith
tissue speciﬁcity in liver and testis [29]. The promoter contains
canonical TATA and CCAAT boxes and several consensus sequences of
the sterol-regulatory elements (SRE-1) [30]. Additional regulatory
factors that are involved in the sterol-mediated transcriptional
regulation have been identiﬁed. A 6 base-pair sequence ATTGGC
recognized by either NF-Y or Sp1 transcription factors has been
demonstrated to be necessary for sterol regulation in the rat FDPS
[31,32]. A second element, termed SRE-3, is required both for sterol-
regulated transcription and for binding of sterol regulatory element
binding protein 1 (SREBP-1) [33,34], whereas a negative regulator of
FDPS transcription has been identiﬁed as Yin and Yan 1 protein (YY1)
[35]. To date human FDPS gene expression has been poorly character-
ized, therefore the current investigations were designed to speciﬁcally
characterize the human FDPS gene promoter. We have cloned the 5′-
ﬂanking region of the human FDPS gene and characterized two cis-Fig.1. Structure of the human FDPS gene and expression pattern of FDPSmRNA in human tiss
accession numbers NM_002004 and NT_004487; the numbers above horizontal lines indica
extension is gray-shadowed; exon sizes are indicated inside the boxes. (C) Bioscience Clonte
muscle, kidney, pancreas, thymus, spleen, prostate, testis, small intestine, ovary, peripheral bl
PCR ampliﬁcations using FDPS speciﬁc primer pairs. FDPS F2/R1: the predicted 281 bp PCR p
cycles of ampliﬁcation. FDPS F1/R21: the predicted 260or 183 bp products were ampliﬁed wit
PCR products were ampliﬁed with primers complementary to exon 1 and exon 2 sequences.
was included as a control for RNA quality and normalization. DNA size markers are shown
GAPDH); N, control PCR reaction with no added template.acting sequences, not investigated previously, which are highly
conserved in human and chimpanzee FDPS gene upstream sequences.
Material and methods
RT-PCR
Multiple Tissue cDNA panels (MTC™ panel I and II, BD Biosciences
Clontech) were utilized for semi-quantitative FDPS expression
analysis by polymerase chain reaction (PCR) [36]. MTC™ panels I
and II consist of ﬁrst-strand cDNAs generated using Oligo-dT by poly
(A)+RNA isolated from sixteen different human tissues: heart, brain,
placenta, lung, skeletal muscle, liver, kidney and pancreas for panel I;
thymus, spleen, prostate, testis, small intestine, ovary, peripheral
blood leucocytes and colon for panel II, respectively. The cDNA
preparations are normalized to the mRNA expression levels of fourues. (A) Exon–intron structure of the human FDPS genewas deduced byMGAlignIt using
te the introns length; (B) Schematic representation of exons (1 to 11); alternative exon
ch derived from poly(A)+ RNA extracted from heart, brain, placenta, lung, liver, skeletal
ood leukocyte colon human normal tissues, and HeLa cells were analyzed by performing
roduct was ampliﬁed with primers complementary to exon 3 and 4 sequences, using 38
h primers complementary to exon 2 and exon 3 sequences. FDPS R11/R7 932 and 220 bp
GAPDH: the ∼1 kb GAPDH product of ampliﬁcation obtained from the same tissue panel
in lane M (1 kb ladder for panel F2/R1, and Gene ruler for panels F1/R21, F11/R7 and
229M.G. Romanelli et al. / Genomics 93 (2009) 227–234different housekeeping genes: α tubulin, β actin, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and phospholipase A2. FDPS
speciﬁc primerswere the following: primers F1, F2, R1 and R7 and R21,
complementary to sequences in exon 2, 3 (F) and sequences in exon 4,
2 and 3 (R), respectively, were derived by mRNA sequence GenBank
accession no. NM_002004. Primer F11 complementary to sequences in
exon 1was derived by contig entry GenBank accession no. NT_004487.
Primer positions are schematically indicated in Fig. 1 panel A, their
sequences are listed in Table 1. PCR cycling conditions were 20 s at
95 °C, 20 s at 62 °C,1min at 72 °C for 34 cycles and a ﬁnal extension for
3 min at 72 °C. Sense 5′-TGAAGGTCGGAGTCAACGGATTTGGT-3′ and
antisense 5′-CATGTGGGCCATGAGGTCCACCAC-3′ primers, speciﬁc to
GAPDH sequences, were used in control analysis for tissue expression
pattern of a housekeeping gene, according to the manufacturer's
recommendations. Aliquots of each ampliﬁed product taken after 28,
30, 35 or 38 cycles, respectively, were analyzed by electrophoresis on
1.5 or 3% agarose gels and visualized by SYBR Safe DNA gel stain
(Invitrogen). All the PCR products were sequenced and analyzed by
sequence alignment to the reference genomic sequence.
Cloning of the 5′-ﬂanking region of the human FDPS
A 5′-upstream region of the human FDPS gene was ampliﬁed by
PCR from human genomic DNA with F3 and R2 primers (Table 1)
derived by contig entry GenBank accession no. NT_004487 genomic
sequences and positioned at −718 and +118 relative to the ﬁrst
nucleotide in the mRNA sequence reported in NM_002004, respec-
tively. Hind III and Kpn I restriction endonuclease recognition sites
were introduced at their ends. We used the following cycling
conditions: initial denaturation at 95 °C for 5′, 30 cycles at 95 °C for
20 s, annealing temperature decreasing 1° every second cycle from
72 °C to 56 °C for 20 s, 72 °C for 1′, further 15 cycles at 95 °C for 20 s,
56° for 20 s, 72° for 1′, and ﬁnal extension at 72 °C for 5′. A fragment of
819 bp was ampliﬁed and cloned into pGL3-basic vector (Promega).
The isolated and cloned genomic fragment was sequenced at the BMR
Genomics facility (http://www.bmr.genomics.it).
In silico analysis of the promoter region
Exon–intron structure of the human FDPS gene was partially
deduced by MGAlignIt at site http://origin.bic.nus.edu.sg/mgalign/
mgalignit [37]. Splice sites and alternative splice sites were obtained
by application of the following programs: Splice site prediction byTable 1
Primer pairs for PCR and mutagenesis
Prime name Positiona,b Primer sequence
F1 +24 to +42a 5′-TGGTTGAGATCTGTGGGGGTCT-3′
F2 +207 to +229a 5′-ATGAACGGAGACCAGAATTCAG-3′
F3 −718 to −696b 5′-TCGGGTACCGTATTTTTAGTAGAGACGGGGT-3′
F4 −364 to −343b 5′-TCGGGTACCAGACAGGCAGCCAAAGCCACAG-3′
F6 −382 to −361b 5′-TCGGGTACCATAATGAAAACTTGAGTAAGAC-3′
F7 Δ OCT-1 −397 to −358b 5′-CAGCTGCCCAGGAAGCTTGAGTAAGACAGG-3′
F8 Δ Pax5 −264 to −225b 5′-TCGTCCGTCACAGTGCCATGCTCACACGAC-3′
F11 +73 to +92b 5′-ATACTGTGAGGCATCGGAAG-3′
F14 −60 to −41b 5′-CATGGTACCGCGGATTCTGCTTTTAGGAG-3′
R1 +466 to +488a 5′-CAGTTCCACACACCAGCCCACA-3′
R2 +98 to +118a 5′-CTCAAGCTTCTTCAAAACGGACACAACAG-3′
R4 Δ OCT-1 −358 to −397b 5′-CCTGTCTTACTCAAGCTTCCTGGGCAGCTG-3′
R5 Δ Pax5 −225 to −264b 5′-GTCGTGTGAGCATGGCACTGTGACGGACGA-3′
R7 +984 to +1004b 5′-GGTTCCTCTGTCCACGCTTG-3′
R21 +206 to +187a 5′-TCTGAGGGAGGAGCAAAGGG-3′
a Positions are relative to nucleotides numeration of the mRNA sequence ref.
GenBank accession no. NM_002004 mRNA (positive numeration).
b Positions are relative to the distance from the ﬁrst nucleotide of the mRNA
sequence ref. GenBank accession no. NM_002004, derived by contig sequence GenBank
accession no. NT_004487. Bold characters indicate the sequence relative to the
restriction sites introduced at the primers ends.Neural Network at BDGP (Berkeley Drosophila Genome Project, www.
fruitﬂy.org/seq_tools/splice.html) [38]; ASSP (alternative splice site
predictor at web site: www.es.embnet.org/∼mwang/assp.html) [39],
and NetGen2 server at web site: www.cbs.dtu.dk/services/NetGene2/
[40,41]. The genomic sequence of 819 bp upstream the FDPS gene was
analyzed for putative promoter sequence using PromoterInspector
software at site http://www.genomatix.de/cgi-bin/eldorado/main.pl
and for potential transcription binding using TRANSFAC Transcription
Factor Binding Sites Database [42] at site http://www.gene-regulation.
com/ and MatInspector at site http://www.genomatix.de/cgi-bin/
eldorado/main.pl. Alignments of the genomic sequences from
human, mouse, rat, chimpanzee and dog were derived by BLAST and
BLAT [43] analyses, carried out comparing the upstream sequences of
FDPS against genomic sequences from a range of organisms in the
database at http://www.ncbi.nlm.nih.gov/blast/Blast.cgi and the gen-
ome browser at http://genome.ucsc.edu.
Promoter constructs and deletion mutants
A series of human FDPS promoter–luciferase constructs was
generated by PCR using the 819 bp cloned genomic fragment as
template, a common antisense primer R2 containing a Hind III
restriction site and, alternatively, the F3, F4, F6 and F14 sense primers
containing a Kpn I restriction site (Fig. 2). The PCR products were
digestedwithHind III andKpn I and, successively, sub-cloned into pGL3-
Basic Vector (Promega) containing the luciferase reporter gene. In order
to delete the ATAATGAAAA sequence relative to the putative OCT-1
(POU2F1) cis-element at position −382 into the pGL3 −718/+118
construct, we used the F7 Δ OCT-1 and R4 Δ OCT-1 mutated primers.
The sequence relative to the putative Pax5 (PAX5) cis-element at
position-249 was mutagenized from the pGL3 −718/+118 construct
using the F8 ΔPax5 and R5 ΔPax5 mutated primers lacking the
CCACAGTGC sequence. A construct deleted in both OCT-1 and Pax5
putative cis-elements was generated introducing the Pax5 mutation in
theOCT-1 deletedmutant. A promoterless clone [−60/+118]was created
with primers F14/R2 from the pGL3 −382/+118 construct. PCR products
were digested with Hind III and Kpn I and sub-cloned in pGL3-Basic
vector. Primers sequences are shown in Table 1. Each construct was
sequenced from both ends in order to check the correct orientation
and ﬁdelity.
Cell culture
Adherent HeLa cells were maintained in exponential growth in
Dulbecco's modiﬁed Eagles medium (Cambrex) supplemented with
10% fetal calf serum (Cambrex), glutamine (2.0 mM), and gentamycin
(50 μg/ml) at 37 °C in 5% CO2.
Transient cell transfection and luciferase assay
24 h before transfection, cells were plated in a 24-wells plate at a
density of 8×104 cells/well, and allowed to grow under normal culture
conditions. Promoterless ﬁreﬂy luciferase reporter vector pGL3-basic
was used as a negative control in all assays. 1 ng of the plasmid phRL-
TK (Promega) containing the Renilla ﬁreﬂy gene and 0.6 μg of pGL3-
reporter vectors containing the FDPS promoter sequences were co-
transfected in each well using Polyfect reagent (Quiagen). Transfected
cells were harvested 24 h later with Dual-Luciferase Reporter Assay
System buffer (Promega) and luciferase activity was measured in each
cell lysate by luminometry. FDPS promoter–luciferase activity in
transfected cells was normalized to Renilla luciferase activity derived
from the phRL-TK vector. Data were analyzed as fold expression
relative to luciferase activities of the promoterless pGL3-Basic vector.
All assays were performed at least three times in triplicate. Results are
presented as mean±SD. Statistical signiﬁcance was determined using
the Student's t-test. A p-value of b0.05 was considered signiﬁcant.
Fig. 2. Nucleotide sequences of the 5′-ﬂanking region of the human FDPS and sequence alignment of FDPS orthologs. (A) 5′ upstream FDPS gene human genomic sequence. Putative
transcription factor-binding sites and cis-acting elements are underlined and labelled: CAC-box, Sp1, YY1, c-June, OCT-1, Sp1, NF-Y, Pax5, SRE3, AP2, TATA-box. The ﬁrs nucleotide in
the mRNA sequence in GeneBank NM_002004 is indicated as +1 and framed. The intron 1 sequence is indicated as IVS-1. Primers utilized in PCR ampliﬁcations to produce constructs
pGL3 −718, −382, −364, or −60/+118 are indicated by dotted arrows. The ATG codon indicating the translation start site is in grey. (B). Multiple alignment of genomic upstream
sequences of FDPS orthologs. Alignments obtained by BLATanalyses of genomic human, chimpanzee, rat, mouse and dog sequences are shown. Asterisks indicate nucleotides identity
in all aligned sequences. Putative transcription binding site for OCT-1, NF-Y, Pax5 and SRE3 factors are framed.
230 M.G. Romanelli et al. / Genomics 93 (2009) 227–234Chromatin immunoprecipitation (Chip) assay
To determine the binding of OCT-1 and Pax5 factors to FDPS
promoter, ChIP assays were performed with the EpiQuik™ Chromatin
Immunoprecipitation kit based on the protocol provided by the supplier(Epigentek Group Inc., Brooklyn, NY). Immunoprecipitations were
performed on samples of 1×106 HeLa cells. Cellular components were
cross-linked by incubation of HeLa cells with 1% formaldehyde at room
temperature for 10′; the reaction was stopped by addiction of glycine
(ﬁnal concentration 125 mM). Nuclei were extracted by centrifugation
231M.G. Romanelli et al. / Genomics 93 (2009) 227–234after incubation of the sample with a pre-lysis buffer on ice for 10′; the
pelletwas resuspended in a lysis bufferwith a protease inhibitor cocktail
and incubated on ice for 10′. DNAwas sheared by sonication (4 pulses of
10 s at 14 μm Amplitude with an MSE Soniprep 150 Ultrasonic
disintegrator) to produce fragments between 200–1000 bp. After
centrifugation, cell debris was discarded; an aliquot of DNA-containing
supernatant was analyzed on agarose gel to check the shearing of DNA
samples. An aliquot of DNA-containing supernatant was removed as
“input” DNA and stored on ice. DNA samples diluted with ChIP dilution
buffer were transferred into the strip wells previously precoated with
the antibody against human OCT-1 (Santa Cruz Biotechnology, Inc.),
Pax5 (Abcam), RNA polymerase II (Abcam), or non speciﬁcmouse IgG (a
negative control provided by the kit supplier), respectively. Incubation
was at room temperature for 90′ on an orbital shaker at 100 rpm.Wells
were washed 6 times with a wash buffer (allowing 2′ on an orbital
shaker at 100 rpm for eachwash) and oncewith TE buffer (Tris–HCl, pH
8, 1 mM EDTA). Precipitated DNA–protein complexes and the input
samplewere treatedwith proteinase K (250 μg/ml) and the DNA release
buffer for 15 min at 65 °C and subsequently incubated in reverse buffer
for 90′ at 65 °C to obtain the cross-linked DNA reversal reaction. DNA
samples were ﬁnally collected by spin column, washed with 70% and
90% ethanol and then eluted from the column with the elution buffer.
Puriﬁed DNAs were analysed by PCR utilizing primers speciﬁc for FDPS
promoter regions relative to the OCT-1 and Pax5 putative cis-acting
signals, respectively. PCR assays were performed using the GoTaq®
Mastermix (Promega) under the following condition: hot start at 95 °C
for 2′ , denaturation 95 °C for 30 s, annealing at 57 °C for 30 s, extension
at 72 °C for 30 s andﬁnal extension at 72 °C for 5′. Primers speciﬁc for the
predictedOCT-1 and Pax5 consensus region in the FDPS promoterwere:
ChIP_Oct1-1F 5′-TGCTGCGTTTTACTAACGTG-3′ and ChIP_Oct1-1R 5′-
CAATGGAAGGGCTGAAGTC-3′; ChIP_Pax5-1F: 5′-GAGTAAGACAGG-
CAGCCAAA-3′ and ChIP_Pax5-1R: 5′-GGACAGATAACGCGATCCT-3′. Pri-
mers for the RNA polymerase II binding region in the GAPDH promoter
(positive control)were the following:GAPDH-F: 5′-GAGCGGTGCTGGGC-
TCCGGCTCC-3′ and GAPDH-R: 5′-GCAGCAGGACACTAGG-3′. Primers for
a chromosome 16 centromere (16cen) region (negative control) wereFig. 3. 5′-deletion functional analysis of the human FDPS promoter in HeLa cells. Schematic re
of different lengths cloned into pGL3-basic vector are shown. The empty and grey coloured
luciferase fusion constructs or the promoterless vector were transiently transfected into He
relative to the construct −382/+118, which activity is set to 100%. The results are the mea
statistically signiﬁcant difference compared to the −382/+118 construct evaluated by the Stthe following: 16cen-F: 5′-GTCTCTTTCTTGTTTTTAAGCTGGG-3′ and
16cen-R5′-TGAGCTCATTGAGACATTTGG-3′. PCRproductswere analysed
on a 2% agarose gel, stained with ethidium bromide and visualized on a
UV transilluminator.
Results and discussion
FDPS gene organization and mRNA expression in human tissues
A human FDPS cDNA coding for a putative protein of 353 amino
acids has been initially isolated by screening human hepatoma cell
line (HepG2) and placental cDNA libraries [20]. A longer transcript,
1345 bp in length that codiﬁes for a peptide of 419 amino acids is
actually attributed to the mRNA sequence of human FDPS gene
deposited into GenBank entry NM_002004. These two peptides have
been recently described as isoforms of the same FDPS enzyme with
speciﬁc sub-cellular distributions: one is detected preferentially into
the peroxisomes and another, containing an N-terminal extension of
66 amino acids, is destined to the mitochondria [25]. This speciﬁc
dual sub-cellular localization of the FDPS enzyme seems to be
widespread among eukaryotes [25]. The human FDPS gene maps on
chromosome 1q22 with location starting at 153,545,267 (NC
000001.9) and extending for 11,814 nucleotides. Ten related pseudo-
genes have been recognized in the human genome, mapping on six
different chromosomes [44,45], A. F. Scott, Personal communications,
11/9/2006, Baltimore, MD]. Multiple transcription start sites have
been identiﬁed in the 5′ region of human FDPS by 5′ RACE [20,25].
Few studies have attempted to describe the complex organization of
the 5′ region of the gene. A detailed study of “Martin et al. [25]”
indicates that at least three different transcription start sites can be
positioned at −136,−36, and −29, respectively, relative to the ﬁrst ATG
codon in exon 1. From both the genomic information (NT_004487)
and the mRNA sequence (NM_002004) relative to FDPS sequence
deposited in the NCBI database we derived a map of the exon–intron
boundaries of the gene applying the MGAlignIt algorithm. A
summary of the genomic organization and splicing pattern of thepresentation of the promoter–reporter constructs containing FDPS promoter fragments
ovals indicate the Pax 5 and OCT-1 consensus sequences, respectively. The promoter–
La cells. Luciferase activity was normalized to Renilla ﬁreﬂy activity and expressed as %
n±SD from at least three independent experiments performed in triplicate.⁎ Denotes
udent's t test (pb0.05).
Fig. 4. Determination of OCT-1 and Pax5 binding site to the FDPS promoter by the ChIP
assay. PCR ampliﬁcation products obtained by DNA immunoprecipitated with
antibodies (Ab) against OCT-1, Pax5, RNA pol II, non speciﬁc IgG or unimmunopreci-
pitated (input) from HeLa cells were analyzed into a 2% agarose gel stained with
ethidium bromide. Primer pairs speciﬁc for the RNA polymerase II binding region of
GAPDH promoter (positive control), 16cen (negative promote region), OCT-1 or Pax5
binding sequences of FPDS human promoter were utilized for each sample indicated on
the top line, expecting fragments of the following size: 111 bp from GAPDH promoter,
207 bp from 16cen, 157 bp fragment encompassing the OCT-1-binding region of the
FDPS promoter and 212 bp fragment encompassing the Pax5 binding region of the FDPS
promoter. Negative control represents the PCR product in absence of template. MWM,
100 bp DNA molecular marker.
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site predictor, ASSP and NetGen2, including the recent published
results of splicing organization, is represented in Fig. 1 panels A and B.
The coding sequence, organized in eleven exons, predicts a 439 aa
peptide. Alternative isoforms can be derived by the presence in exon
1 and in the intron sequence between exon 2 and 3, of two
alternative 5′ donor sites and 3′ acceptor sites (Fig. 1 panel B). The
two ATG codons positioned in exon 2 and 3, respectively, may
represent the ﬁrst codon of each isoform, the mitochondrial and the
cytoplasmic one. Interestingly, the complex processing of the ﬁrst
exon occurs as well in other organisms, where different isoforms can
be identiﬁed [24,29]. Analyses in the human EST sequence databases
identify two major transcripts: one including both exon 1 and intron
1, which is expressed preferentially in fetal brain tissue and another,
lacking intron 1, which shows widespread expression. Human FDPS
expression has been prevalently studied in cell lines, i.e. hepatic cell
line, monocytic leukaemia cell line, CaCo2, HT29, K562 (human
erythroleukemia cell line), human proximal tubule cell line (HK-2)
and HeLa cells: these studies pointed out the regulatory expression
by phorbol ester and the presence of splicing variants [25,46,47,48].
In order to integrate cell lines data we investigated the FDPS mRNA
expression in human tissues by semi-quantitative RT-PCR on two
panels of poly(A)+RNA derived from sixteen different human tissues:
heart, brain, placenta, lung, liver skeletal muscle, kidney, pancreas,
thymus, spleen, prostate, testis, small intestine, ovary, peripheral
blood leukocyte, colon and HeLa cells. The results are shown on Fig. 1,
panel C. Relative amounts of RNA can be compared thanks to the
GAPDH transcript control (one of the housekeeping genes utilized to
normalize the polyA RNAs present in the panel). Initially, we analyzed
the expression of FDPS mRNA utilizing primers that recognize exon 3
and exon 4 sequences which are not involved in alternative splicing,
according to the “in silico” splicing analyses. In all tissues analyzed, a
unique band of the expected 281 bp size was ampliﬁed (Fig. 1 panel C,
FDPS F2/R1), indicating that the FDPS human gene is transcribed
ubiquitously. We successively analyzed the expression of the putative
alternative splicing isoforms derived by arrangements between exon
2 and 3. Using a pair of primers that overlap sequences into exon 2
and 3 (Fig. 1, panel C, FDPS F1/R21), two bands were detected. One,
which is present in all tissues, corresponds to the expected 183 bp
fragment; the second slower band of 260 bp derives by inclusion of a
77 bp intron between exon 2 and 3, as determined by direct
sequencing of the two fragments. In the third set of ampliﬁcations,
shown in panel FDPS F11/R7, we analyzed the expression of the
isoforms derived by alternative processing of exon 1. Primer F11 is
located 73 bp downstream the ﬁrst nucleotide in the ref seq
NM_002004 and deduced by genome ref seq NT_00448 relative to
the ﬁrst intron. This analysis showed two different ampliﬁcation
products that derive from the intervening sequence between exon 1
and 2 and that can be spliced using alternative 5′ donor (GT) sites and
3′ acceptor (AG) sites. An ampliﬁcation product of 220 bp derived
from the 712 bp intron exclusion, is well represented in all tissues. A
second, less represented band of approximately 900 bp is also
ampliﬁed in almost all tissues. This latter transcript derives from the
712 bp intron inclusion thereby leading to an ampliﬁcation product of
932 bp. The inclusion of the 712 bp sequence in at least one of the
RNA forms was conﬁrmed by ampliﬁcation of a speciﬁc fragment
using an antisense primer positioned inside the intron (data not
shown). The sizes of the fragments obtained by ampliﬁcation were all
conﬁrmed by sequencing. These results are consistent with what
reported by “Martin et al. [25]” that indicate the presence of two
predominantly FDPS isoforms: a shorter cytosolic/peroxisomal form,
and a longer isoform, representing the mitochondrial targeting
peptide derived by alternative splicing in the ﬁrst exon. Altogether
these results indicate that the FDPS gene is transcriptionally
expressed in all human tissues and is represented by a variety of
transcripts, not equally represented.Cloning and sequence analysis of the 5′-ﬂanking region of the human
FDPS gene
The 5′-ﬂanking region of FDPS gene was isolated by genomic PCR,
with a pair of primers spanning the sequence −718+118, respectively,
derived by contig NT 004487. Sequencing of the ampliﬁed fragment
allowed its alignment with the updated version in the human genome
database and showed 100% identity. Computer-based analysis of the
sequence using MatInspector, V2-2 software (core similarity 1, matrix
similarity 0.90) using Transfac 4.0 matrices [49], revealed several
putative potential cis-acting signals (Fig. 2, panel A). Some of them are
conserved in the rat promoter sequences [30] and in the promoters of
sterol regulatory element-binding protein-responsive genes, i. e. 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase
(HMGCS1), and the low density lipoprotein receptor (LDLR) and
have been functionally characterized previously [32,35]. More
speciﬁcally, the proximal 5′ ﬂanking region of the FDPS gene contains:
a TATA box at −128; an AP2 (activator protein 2) at position −159; a
NF-Y (nuclear factor Y) at −215 and a SRE-3 at −233 that were well
characterized in the rat FDPS promoter, HMG-CoA and LDLR
promoters. It was demonstrated that SREBP and NF-Y may interact
synergistically enhancing the transcription of the gene [34,35]. At
position −269 is located an NF-Y consensus site, characterized
previously in the rat promoter as a cis-acting signal required for
normal transcriptional regulation by cellular sterols, and an YY1
consensus site is found at −239. Other putative cis-acting signals not
previously characterized are a Pax5 binding site at position −249, a
Sp1 site at position −370, an OCT-1 binding site at position −382, a
more distal SP1/YY1/C-jun site at position −558, and a CAC-box at
position −607. Multiple sequence alignment comparing this 5′
upstream genomic sequence of human FDPS to chimpanzee (chromo-
some 1 of Pan troglodytes), mouse (chromosome 5 of Mus musculus),
rat (chromosome 2 of Rattus norvegicus) and dog (chromosome 7 of
Canis lupus familiaris) utilizing BLAT program, identiﬁed two highly
conserved regions overlapping the putative Pax5 and OCT-1
233M.G. Romanelli et al. / Genomics 93 (2009) 227–234transcription factors binding sites, respectively, in the human and
chimpanzee genomes, which are not present in the promoter region of
the other examined orthologous genes (Fig. 2, panel B). The in silico
analysis suggests that these two conserved regions may play a
primate-bound role in the functionality of the FDPS promoter region.
Functional analyses of the human promoter of FDPS and of the
contribution of two conserved cis-acting signals
To identify the sequences that are necessary for basal transcription
of human FDPS, we analyzed by reporter gene assays a set of 5′
deletions of the promoter region generated by PCR of genomic
sequences. The primers used for identiﬁcation of the promoter activity
are shown in Fig. 2, panel A (dotted arrows). The 819 bp genomic
fragment was cloned 5′ to the ﬁreﬂy luciferase reporter gene of the
pGL3-basic plasmid. The resulting plasmid pGL3 −718/+118 was used
as a template for the generation of four progressively upstream
deleted fragments that were cloned separately in the Promoterless
luciferase vector and transiently transfected in HeLa cells.
The results of luciferase activity expressed by the reporter vectors
are shown in Fig. 3 as percent relative to construct −382/+118 which
contains the portion of human FDPS promoter region homologous to
the functionally characterized rat FDPS promoter region [30].
Transfection of HeLa cells performed with pGL3 −718/+118, showed
almost the same promoter activity of the shorter promoter sequence
in −382/+118; differences in the repeated experiments of these
construct, were not statistically signiﬁcant. When the putative Pax5 or
OCT-1 binding sites were deleted, a statistically signiﬁcant (pb0.05)
increase in activity was observed in constructs −364/+118 (+43%),
ΔOCT-1 (+25%), Δ Pax5 (+38%), respectively. Deletion of both cis-
acting sequences in construct −718/+118 ΔOCT-1/Δ Pax5 showed a
13% increase of promoter activity compared to that of −382/+118.
Finally, construct −60/+118, deleted of all the putative cis-acting
signals, showed a decrease of expression near to zero, as expected. All
together these results indicate that the minimal sequence which is
essential to drive transcription of FDPS with the highest luciferase
activity spans nucleotides from −364 to −60 and that the putative
Pax5 and OCT-1 elements modulate the activity of the promoter
region.
Cellular OCT-1 and Pax 5 binding to the cognate cis-elements in the FDPS
promoter
To test whether OCT-1 and Pax 5 trasncription factors bind to the
FDPS promoter region we isolated and analyzed chromatin from HeLa
cells by Chip assay. After immunoprecipitationwith either nonspeciﬁc
IgGs or with antibodies against OCT-1, Pax5, RNA pol II, respectively,
PCR reactions were performed with speciﬁc primers. Using an equal
amount of chromatin “input” we obtained the ampliﬁcation products
that are shown in Fig. 4. A 157 bp fragment containing the binding site
for OCT-1 and a fragment of 212 bp containing the binding site for
Pax5 were ampliﬁed from chromatin fragments immunoprecipitated
with antibodies against OCT-1 and Pax5 respectively. No ampliﬁcation
products were obtained either by chromatin immunoprecipitated
with non speciﬁc IgGs or with RNA polymerase II antibodies. These
results indicate that OCT-1 and Pax 5 transcription factors do actually
interact with cis-acting sequences in the human FDPS promoter.
Conclusions
In the present work we have reported the following results:
a) Expression of FDPS transcripts in adult human tissues: this
analysis revealed that FDPS mRNAs are expressed ubiquitously,
and that various splicing variants unevenly distributed in the
different tissues can be detected.b) Cloning and characterization of the FDPS promoter region and
identiﬁcation of the minimal promoter region: the minimal
promoter located between −364 and +118 contains a TATA box
and putative cis-acting signals that are highly conserved in
orthologous genes. Further luciferase reporter expression
analyses of deleted constructs indicated the presence of
putative negative cis-acting signals between −382 and −239.
c) Identiﬁcation of two conserved sequences restricted to the
primate promoter region of the FDPS gene, ATAATGAAAAC at
−382 and CCACAGTGC at −249 that can be recognized by OCT-1
and Pax5 transcription factors, respectively. We believe that the
data presented here may add useful information for further
genetic and pharmacogenetic studies, in the light of recent
insights into the correlation of FDPS polymorphic variants with
lipid metabolism and bone mineral density [28,50].
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